Customize your JAMA Network experience by selecting one or more topics from the list below.
Author Affiliations: Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Background Human growth hormone (HGH) and insulin-like growth factor-1 (IGF-1) have been shown to play a role in the malignant transformation and progression of a variety of cancers. HGH is also known to upregulate molecular signaling pathways implicated in the pathogenesis of melanoma. Although HGH has previously been implicated in promoting the clinical growth of both benign and malignant melanocytic neoplasms, to our knowledge there are no conclusive studies demonstrating an increased risk of melanoma following HGH therapy. Nevertheless, there are reports of melanoma developing subsequent to HGH coadministered with either other hormones or following irradiation.
Observation A 49-year-old white man presented with a new pigmented papule that was diagnosed as melanoma. The patient reported using HGH for 3 months prior to the diagnosis. His 51-year-old wife, who also was white, had also been using exogenous HGH for 3 months and had been diagnosed as having a melanoma 2 weeks prior.
Conclusions Given the unlikelihood of 2 unrelated people developing melanoma within a short time span, it is reasonable to assume that a common environmental component (HGH or other shared exposure) contributed to the development of both melanomas. Because of the increased use of exogenous HGH as an antiaging agent, it is important to be aware of the growth-promoting effects of this hormone. Until better data are available that determines the true risk of exogenous HGH, its use as an antiaging agent merits increased surveillance.
We report 2 cases of new-onset cutaneous melanoma subsequent to the initiation of exogenous human growth hormone (HGH), an anabolic peptide hormone synthesized by the anterior pituitary gland. Endogenous HGH secretion is regulated by growth hormone–releasing hormone (GHRH) produced in the hypothalamus. Most of HGH's effects on growth and metabolism are mediated by insulin-like growth factor 1 (IGF-1). IGF-1 is produced primarily in the liver following stimulation by HGH. The use of exogenous HGH as an antiaging agent is gaining acceptance and increasing in prevalence despite its negative adverse effects,1,2 including oncogenic transformation and neoplastic progression.3
Human growth hormone's direct effects are predominantly mediated through the mitogen-activated protein kinase/extracellular-signal–regulated kinase (MAPK/ERK)4 and janus kinase signal transducer and activator of transcription (JAK-STAT)5 pathways. IGF-1 directly upregulates the MAPK/ERK6 and phosphoinositide 3-kinase (PI3K)7 pathways. Given that overstimulation of these pathways has been implicated in the pathogenesis of melanoma,8 there may be indication to closely monitor patients using exogenous HGH for development of malignant disease.
A 49-year-old white man presented with a new pigmented papule on his left lower back (Figure 1 and Figure 2). A biopsy was performed, and findings were consistent with a diagnosis of melanoma (Breslow depth, 0.32 mm) (Figure 3). Although there was no family history of melanoma among his genetic relatives, his 51-year-old wife, who also was white, had been diagnosed as having a melanoma on the right arm 2 weeks prior (Breslow depth, 0.75 mm). Both patients noted that 3 months previously they had begun an antiaging regimen that included exogenous HGH. The man's regimen included daily subcutaneous injection of HGH (0.58 mg) and testosterone. His wife's regimen included daily subcutaneous administration of HGH (0.29 mg) plus topical testosterone, progesterone, and estrogen to her inguinal region and axillae. On discovery of the melanomas, both discontinued their exogenous hormone regimens.
Figure 1. Clinical image revealing an 8-mm melanocytic lesion on the male patient's left lower back at the waistline. It did not match the pattern of his other moles, and he and his wife indicated that it was new.
Figure 2. Dermoscopic features of a lesion on the male patient. These include irregular pigment network, nonuniform borders with streaks at approximately the 9- to 10-o’clock position and peripheral dots at approximately the 11- to 2-o’clock position, and a bluish-white veil.
Figure 3. Histopathologic review of a specimen from the male patient. A and B, Findings revealed disorganized and noncohesive melanocytic cells at the dermal epidermal junction with nests and single melanocytic cells noted in the dermis with lymphocytic infiltration and pigmented macrophages with superficial dermal fibrosis and scattered melanocytic cells in the upper levels of the epidermis. (Hematoxylin-eosin, original magnification ×40.)
There is one similar report in the literature of a 26-year-old woman who developed melanoma following hormone therapy with HGH, thyroid hormone, and estrogen.9 Although this report suggested that estrogen replacement was the causal agent, it could not rule out the role of HGH via the Naranjo adverse drug reaction causality algorithm. Although estrogen has been implicated as a risk factor in the development of melanoma,10 subcutaneously administered exogenous HGH was the only agent common to all 3 regimens.
It is well established that pigmentation is regulated by a variety of signaling pathways, including peptide hormones.11 Consequently, it is possible that there exists a direct correlation between exogenous HGH administration and the development of melanoma. This correlation may also extend to benign melanocytic neoplasms. Supporting evidence includes a previous study that demonstrated that administration of exogenous HGH accelerates the rate of nevus growth.12 There is also evidence that nevi in individuals treated with HGH exhibit abnormal melanosome architecture, increased Ki-67 staining, and increased anisokaryosis compared with matched controls.13 However, it should be noted that other studies of patients failed to confirm this correlation.14-16
Although the aforementioned series did not demonstrate the development of melanoma in any of the patients younger than 18 years, there is a report of malignant melanoma developing in both a 9-year-old girl and 15-year-old boy following 3.0 and 1.5 years of exogenous HGH replacement, respectively.16 One aspect unique to both of these cases was that the patients had previously received craniospinal irradiation. Consequently, an underlying mutation generated by irradiation could have primed the melanocytes to grow in response to the HGH in an abnormal manner. Meanwhile, it is likely that minors studied in the other reports did not contain predisposing mutations when treated with HGH and thus were less susceptible to tumor growth. Finally, it is possible that predisposing UV-induced mutations that accumulated over time in sun-damaged skin primed the 2 cases of melanoma presented herein to grow in response to HGH. The couple shared outdoor activities in the Florida sun, and the wife had a history of basal cell and squamous cell carcinoma.
Despite the data against a correlation between HGH and benign melanocytic neoplasms, there is molecular evidence that HGH has the potential to play a role in the pathogenesis of melanoma (Figure 4). First, growth hormone receptors (GH-R) are known to be upregulated in malignant melanocytic lesions compared with their benign counterparts.17 Direct stimulation of these receptors results in the upregulation of the MAPK/ERK pathway,4 and thus HGH is likely to contribute directly to the promotion of mitogenic signaling in evolving melanomas. Second, both benign and malignant melanocytes are known to possess receptors for IGF-1,18-20 the major downstream mediator of HGH. As mentioned herein, IGF-1 upregulates the MAPK/ERK and PI3K pathways. It is thus not surprising that IGF-1 inhibits apoptosis7 and accelerates the in vitro growth of malignant melanocytes.21 In addition, interruption of IGF-1 receptor binding has been shown to result in growth inhibition and decreased MAPK signaling.6 The mechanistic data support the notion that IGF-1 may play a role in the progression of early malignant lesions22 in addition to promoting progression and dissemination.23
Figure 4. Exogenous human growth hormone (HGH) stimulates the liver to produce insulinlike growth factor 1 (IGF-1). IGF-1 in turn binds to IGF-1 receptors (IGF-1R) on melanocytes. This both promotes growth through the mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and inhibits apoptosis via the phosphoinositide 3-kinase (PI3K) pathway. Exogenous HGH also directly activates mitogenic signaling pathways by binding to HGH receptors (GH-R) located on melanocytes. GH-R agonism by HGH also causes the endogenous melanocytic production of IGF-1 via the janus kinase signal transducer and activator of transcription (JAK-STAT), which can then feed into the aforementioned signaling loop. Melanocytes also possess growth hormone releasing hormone receptors (GHRH-R). While GHRH-R are known to promote tumorigenesis in other cancer models via cyclic adenosine monophosphate (cAMP), this pathway has not been studied in melanoma. Although other GHRH-R positive cancers did not produce HGH, it is uncertain if GHRH-Rs in melanoma are capable of initiating the synthesis and secretion of GH.
Curiously, melanoma may have an endogenous growth promoting loop for the HGH/IGF-1 pathway. Supporting evidence includes the presence of GH-Rs on melanoma cells24 and the fact that melanoma cells synthesize IGF-1.25 It is also interesting to note that melanomas express growth hormone–releasing hormone receptors (GHRH-Rs).26 Although, to our knowledge, direct production of HGH by melanoma cells has not been noted in the literature, activation of the GHRH-Rs has been shown to have growth-promoting functions in other tumors. Given the proliferative effects of each member of this pathway, specific antagonists to each receptor may also have a therapeutic benefit in melanomas.
Given the unlikelihood of 2 unrelated people developing melanoma within a 3-month period, it is plausible that a common environmental component (HGH or other shared exposure) contributed to the pathogenesis. In this situation, it is possible that HGH provided the growth stimulatory signaling necessary to unmask previously quiescent melanoma clones, thus allowing the tumors to proliferate. Because both HGH and IGF-1 are known to promote malignant transformation and progression,3 it may be necessary to closely monitor patients prescribed HGH antiaging regimens for melanoma.
Correspondence: James M. Grichnik, MD, PhD, Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Room 912, BRB, 1501 NW 10th Ave, Miami, FL 33136 (email@example.com).
Accepted for Publication: April 30, 2012.
Author Contributions: Drs Handler, Ross, Shiman, and Grichnik had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Shiman and Grichnik. Acquisition of data: Elgart and Grichnik. Analysis and interpretation of data: Handler, Ross, and Grichnik. Drafting of the manuscript: Handler, Ross, Shiman, Elgart, and Grichnik. Critical revision of the manuscript for important intellectual content: Ross and Grichnik. Administrative, technical, and material support: Handler, Ross, and Grichnik. Study supervision: Shiman and Grichnik.
Financial Disclosure: Dr Grichnik is a major shareholder for DigitalDerm Inc, has received grants from and done consulting for Spectral Image Inc, and has been a consultant for Genentech.
Funding/Support: This study was supported in part by the Department of Dermatology and the Anna Fund Melanoma Program at Sylvester Comprehensive Cancer Center, University of Miami.
Additional Contributions: The Department of Dermatology, Anna Fund Melanoma Program, and Sylvester Comprehensive Cancer Center at the University of Miami provided ongoing support.
Handler MZ, Ross AL, Shiman MI, Elgart GW, Grichnik JM. Potential Role of Human Growth Hormone in Melanoma Growth Promotion. Arch Dermatol. 2012;148(10):1179–1182. doi:10.1001/archdermatol.2012.2149
Create a personal account or sign in to: